Dag Sehlin, PhD, is an Associate Professor of Neurobiology at Uppsala University. His research focuses on Alzheimer’s disease, developing therapeutic and diagnostic tools, including engineered antibodies targeting amyloid-beta

Dag has played an important role in the research behind the development of Lecanemab, an amyloid-beta antibody recently approved for Alzheimer's treatment by both the FDA in the U.S. and the EMA in Europe.

Episode timestamps:

00:00 - Guest Introduction: Dag Sehlin, Associate Professor of Neurobiology

03:25 - Progression of Alzheimer's Disease in the Brain

05:48 - Comorbidities and Challenges in Diagnosing Alzheimer's

12:54 - Tau and Amyloid Beta Markers in Cerebrospinal Fluid

17:00 - Future Potential of Blood Tau for Early Alzheimer's Detection

24:01 - FDA & EMA Approval of Lecanemab for Alzheimer's Treatment

25:27 - Lecanemab: First Disease-Modifying Alzheimer's Treatment

35:23 - Clinical Benefits of Lecanemab Beyond Cognitive Function (Quality of Life, Hospitalization Rates and More)

58:39 - Dose-Dependent Side Effects and Future Improvements

01:00:54 - Transferrin Receptor "Trojan Horse" Mechanism for Blood-Brain Barrier Penetration

01:15:16 - Neuroinflammation: Beneficial vs. Harmful Effects and Possible Solutions

01:39:37 - AI and Brain Imaging: Enhancing Precision

01:42:04 - Enhancing Collaboration Between Academia and Big Pharma Companies